Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Therapeutics

• Publication date

  2006-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLINTHERA.2006.04.014PMID 16750462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.

  2005cited by this paper
• Virtual Colonoscopy

  2005cited by this paper
• A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.

  2005cited by this paper
• The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety.

  2005cited by this paper
• An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.

  2005cited by this paper
• Eszopiclone

  2005cited by this paper
• PNL30 FORECASTING THE IMPACT OF ADDING A NEW DRUG ON FORMULARY USING MEDICAL CLAIMS DATA AND CLINICAL LITERATURE: A CASE STUDY OF INSOMNIA TREATMENT

  2005cited by this paper
• Pharmacologic management of insomnia.

  2004cited by this paper
• The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents

  2004cited by this paper
• Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam.

  2004cited by this paper
• Normal human sleep: an overview.

  2004cited by this paper
• Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives

  2004cited by this paper
• Measuring treatment efficacy in insomnia.

  2004cited by this paper
• Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia

  2004cited by this paper
• Classifying insomnia in a clinically useful way.

  2004cited by this paper
• Advances in the management of insomnia

  2004cited by this paper
• Sleep, health, and aging....

  2004cited by this paper
• Treatment of primary insomnia.

  2004cited by this paper
• Sleep in the Elderly: Burden, Diagnosis, and Treatment.

  2004cited by this paper
• Is insomnia a neurophysiological disorder? The role of sleep EEG microstructure.

  2004cited by this paper
• Chronic insomnia: current issues.

  2004cited by this paper
• The changing perspective on chronic insomnia management.

  2004cited by this paper
• Sleep, health, and aging. Bridging the gap between science and clinical practice.

  2004cited by this paper
• Clinical and socioeconomic correlates of insomnia.

  2004cited by this paper
• Identification and management of insomnia.

  2004cited by this paper
• The benzodiazepine site of the GABAA receptor: an old target with new potential?

  2004cited by this paper
• Fluctuation of waking electroencephalogram and subjective alertness during a 25-hour sleep-deprivation episode in young and middle-aged subjects.

  2004cited by this paper
• The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.

  2004cited by this paper
• Insomnia: epidemiology, characteristics, and consequences.

  2003cited by this paper
• Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.

  2003cited by this paper
• Transient and short term insomnia

  2003cited by this paper
• New Drugs for Insomnia

  2003cited by this paper
• Practice parameters for using polysomnography to evaluate insomnia: an update.

  2003cited by this paper
• Assessment and management of insomnia.

  2003cited by this paper
• Measuring outcomes in randomized clinical trials of insomnia treatments.

  2003cited by this paper
• Subunit composition, distribution and function of GABA(A) receptor subtypes.

  2002cited by this paper
• Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia.

  2002cited by this paper
• The relationship between insomnia and health-related quality of life in patients with chronic illness.

  2002cited by this paper
• Medications for the Treatment of Sleep Disorders: An Overview.

  2001cited by this paper
• CONSENSUS FOR THE PHARMACOLOGICAL MANAGEMENT OF INSOMNIA IN THE NEW MILLENNIUM

  2001cited by this paper
• (S)-Zopiclone Sepracor.

  2001cited by this paper
• Pyrazolopyrimidines.

  2001cited by this paper
• Future directions in the management of insomnia.

  2001cited by this paper
• Meta-analysis of benzodiazepine use in the treatment of insomnia.

  2000cited by this paper
• Evaluation of chronic insomnia

  2000cited by this paper
• Treatment of late-life insomnia

  2000cited by this paper
• Helping patients who say they cannot sleep

  2000cited by this paper
• Public health and insomnia: economic impact.

  2000cited by this paper
• Evaluation of chronic insomnia. An American Academy of Sleep Medicine review.

  2000cited by this paper
• Why changes in administration of polio vaccine?

  2000cited by this paper
• An American Academy of Sleep Medicine Review

  2000cited by this paper
• Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

  2000cited by this paper
• Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia.

  2000cited by this paper
• Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial.

  1999cited by this paper
• Nonpharmacologic Treatment of Chronic Insomnia

  1999cited by this paper
• Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review.

  1999cited by this paper
• Prevalence and health consequences of insomnia.

  1999cited by this paper
• Zaleplon displays a selectivity to recombinant GABAA receptors different from zolipdem, zopiclone and benzodiazepines

  1999cited by this paper
• Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine.

  1999cited by this paper
• Structure and subunit composition of GABA(A) receptors.

  1999cited by this paper
• Recognition and diagnosis of insomnia

  1999cited by this paper
• Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

  1999cited by this paper
• Insomnia: assessment and management in primary care. National Heart, Lung, and Blood Institute Working Group on Insomnia.

  1999cited by this paper
• The American Psychiatric Press textbook of psychiatry

  1999cited by this paper
• Effects of drugs on sleep.

  1999cited by this paper
• Clinical correlates of insomnia in patients with chronic illness.

  1998cited by this paper
• Management of insomnia.

  1997cited by this paper
• How a general population perceives its sleep and how this relates to the complaint of insomnia.

  1997cited by this paper
• Polysomnographic effects of hypnotic drugs

  1996cited by this paper
• Effects of drugs on sleep

  1996cited by this paper
• Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.

  1996cited by this paper
• Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: an overview of insomnias and related disorders--recognition, epidemiology, and rational management.

  1996cited by this paper
• Form, frequency and burden of sleep problems in general health care: a report from the WHO Collaborative Study on Psychological Problems in General Health Care

  1996cited by this paper
• Practice parameters for the use of polysomnography in the evaluation of insomnia. Standards of Practice Committee of the American Sleep Disorders Association.

  1995cited by this paper
• Structure and pharmacology of vertebrate GABAA receptor subtypes.

  1995cited by this paper
• An Assessment of Short-Acting Hypnotics

  1995cited by this paper
• Clinical Pharmacokinetics of Zopiclone

  1995cited by this paper
• Mental comorbidity of chronic insomnia in general practice attenders using DSM‐III‐R

  1995cited by this paper
• Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.

  1995cited by this paper
• AARC-APT (American Association of Respiratory Care-Association of Polysomnography Technologists) clinical practice guideline. Polysomnography.

  1995cited by this paper
• Biological function of GABAA/benzodiazepine receptor heterogeneity.

  1995cited by this paper
• Economic effects of insomnia.

  1994cited by this paper
• Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial.

  1994cited by this paper
• ABC of sleep disorders. Impact and epidemiology of sleep disorders.

  1993cited by this paper
• Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers.

  1993cited by this paper
• Prevalence and treatment of insomnia in general practice

  1993cited by this paper
• Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site.

  1993cited by this paper
• Update on disorders of sleep and the sleep--wake cycle.

  1992cited by this paper
• Pharmacotherapy: A pathophysiologic approach

  1992cited by this paper
• Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia.

  1992cited by this paper
• The International Classification of Sleep Disorders

  1991cited by this paper
• Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study.

  1991cited by this paper
• Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989.

  1991cited by this paper
• Sleep, sleepiness, and performance

  1991cited by this paper
• Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice.

  1990cited by this paper
• Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?

  1989cited by this paper
• Principles And Practice Of Sleep Medicine

  1989cited by this paper
• The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.

  1989cited by this paper
• A longitudinal study

  1987cited by this paper
• Insomnia and its treatment. Prevalence and correlates.

  1985cited by this paper

• Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD

  2026cites this paper
• Comparative analysis of warm needle moxibustion and gua sha nursing care on sleep quality and psychological stress in insomnia patients undergoing eszopiclone tablet treatment: A retrospective study

  2025cites this paper
• Effects of Antiepileptic Drugs, Carbamazepine and Phenytoin, on Plasma Concentrations of Clozapine and Its N‐Desmethyl and N‐Oxide Metabolites in Japanese Patients With Schizophrenia

  2025cites this paper
• Review of available drugs and non-pharmacological strategies used to treat insomnia

  2025cites this paper
• Lemborexant overdose presenting with mild sedation despite high plasma levels: A case report

  2025cites this paper
• Efficacy and safety of insomnia pharmacotherapies: Convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis.

  2025cites this paper
• Elucidating the Substrate Specificity of Cytochrome P450 Enzymes: Insights into N- and S-Containing Small-Molecule Metabolism

  2025cites this paper
• Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling

  2025cites this paper
• The Evolution of Benzodiazepine Allosteric Modulators: Structural Insights From Historical Milestones to Emerging Innovations in Drug Discovery and Development.

  2025cites this paper
• Shu-Xie decoction alleviates oxidative stress and colon injury in acute sleep-deprived mice by suppressing p62/KEAP1/NRF2/HO1/NQO1 signaling

  2023cites this paper
• Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review

  2022cites this paper
• Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder

  2022cites this paper
• Development of a novel tandem mass spectrometry method for the quantification of eszopiclone without interference from 2-amino-5-chloropyridine and application in a pharmacokinetic study of rat.

  2020cites this paper
• Drug-Assisted Sexual Assaults

  2019cites this paper
• Anti-inflammatory, anti-nociceptive and sedative-hypnotic activities of lucidone D extracted from Ganoderma lucidum.

  2019cites this paper
• Clinical Psychopharmacology for Neurologists

  2018influential citation
• NEUROCHEMICAL, HEMATOLOGICAL AND BEHAVIORAL ALTERATIONS RELATED TO ESZOPICLONE ADMINISTRATION IN RATS

  2018cites this paper
• Sedatives and Hypnotics

  2018cites this paper
• Eszopiclone for persistent negative symptoms in schizophrenia - An unintended N-of-1 study.

  2017cites this paper
• Chapter 41 – Hypnotic Medications: Mechanisms of Action and Pharmacologic Effects

  2017cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Anxiolytics and Sedative/Hypnotics

  2016cites this paper
• Eszopiclone-induced Parasomnia with Suicide Attempt: A Case Report.

  2016cites this paper
• Review of Safety and Efficacy of Sleep Medicines in Older Adults.

  2016cites this paper
• Eszopiclone: Review and Clinical Applications in Chronic and Comorbid Insomnia

  2015cites this paper
• Non-Benzodiazepine Receptor Agonists for Insomnia.

  2015cites this paper
• Symptom burden and medication use in adult sarcoma patients

  2015cites this paper
• Sleep in traumatic brain injury.

  2015cites this paper
• The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use

  2015cites this paper
• Isolation of bergenin from the root bark of Securinega virosa and evaluation of its potential sleep promoting effect

  2015cites this paper
• Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications

  2015cites this paper
• Forensic Aspects of Hypnotic Drugs

  2015cites this paper
• Drug Treatment of Sleep Disorders

  2015cites this paper
• A Method to Assess the Dissipation of the Residual Effects of Hypnotics : Eszopiclone versus Zopiclone

  2014cites this paper
• Chapter Sixteen – Sedative Hypnotics

  2014cites this paper
• Functionalization of Imidazo[1,2‐a]pyridines by Means of Metal‐Catalyzed Cross‐Coupling Reactions

  2014cites this paper
• Avaliação de fungos no metabolismo enantiosseletivo da Zopiclona e análise por eletroforese capilar

  2014cites this paper
• Sucralose, A Synthetic Organochlorine Sweetener: Overview of Biological Issues

  2013cites this paper
• In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving

  2013cites this paper
• The Clinical and Forensic Toxicology of Z-drugs

  2013cites this paper
• Facile synthesis of new imidazo[1,2-a]pyridines carrying 1,2,3-triazoles via click chemistry and their antiepileptic studies.

  2013cites this paper
• Eszopiclone for insomnia.

  2013cites this paper
• Zopiclone for insomnia

  2013cites this paper
• Zaleplon for insomnia

  2013cites this paper
• Benzodiazepine Receptor Agonists and Sleep

  2013cites this paper
• Treatment of Burnout: Overlap of Diagnosis

  2013cites this paper
• A method to assess the dissipation of the effects of residual hypnotics : Eszopiclone versus Zopiclone

  2012cites this paper
• A Method to Assess the Dissipation of the Effects of Residual Hypnotics: Eszopiclone Versus Zopiclone

  2012cites this paper
• Effects of a 15 mg single-dose eplivanserin on respiratory function and sleep structure in patients with mild to moderate chronic obstructive pulmonary disease (COPD)

  2012cites this paper
• Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications

  2012cites this paper
• Pediatric sleep pharmacology.

  2012cites this paper
• GABA and Schizophrenia

  2012cites this paper
• A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study.

  2012cites this paper
• Insomnia (primary) in older people.

  2011cites this paper
• Schlafstörungen im Alter

  2011cites this paper
• Psychomotor Performance After Intake of Zopiclone Compared With Intake of Ethanol: A Randomized, Controlled, Double-Blinded Trial

  2011cites this paper
• GABA and Sleep: Molecular, Functional and Clinical Aspects

  2011cites this paper
• Eszopiclone stimulates the hypothalamo-pituitary-adrenal axis in the rat.

  2011cites this paper
• Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients.

  2011cites this paper
• Desensitization of GABAergic receptors as a mechanism of zolpidem-induced somnambulism.

  2011cites this paper
• Pharmacology of sleep disorders in children and adolescents.

  2011cites this paper
• Chapter 42 – Hypnotic Medications: Mechanisms of Action and Pharmacologic Effects

  2011cites this paper
• Personalized Pharmacotherapy for Treatment Approaches Focused at Primary Insomnia

  2011cites this paper
• Eszopiclone: an update on its use in insomnia.

  2011cites this paper
• Adrenal dysfunction Postoperative Hyperthyroidism Visceral Cataménial headache Ischemic Neuropathic Nociceptive Sleep disorders Miscellaneous Sleep apnea Dermatologic pruritus Restless leg syndrome Chronic fatigue syndrome Nocturnal myoclonus syndrome Lyme disease Obesity hypoventilation syndrome

  2011cites this paper
• Sleep in Patients with Painful Diabetic Peripheral Neuropathy: Impact of Pain, Glucose and Pharmacological Intervention.

  2010cites this paper
• [Not Available].

  2010cites this paper
• Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics

  2010cites this paper
• Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics

  2010cites this paper
• Examining Insomnia in Primary Care: Understanding Current and Developing Management Strategies

  2010cites this paper
• [Pharmacologic treatment of insomnia in children and adolescent psychiatric patients].

  2010cites this paper
• Cytochrome P450 Enzymes

  2010cites this paper
• Insomnia in the Elderly

  2010cites this paper
• Efficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia

  2010cites this paper
• Le traitement pharmacologique de l’insomnie en pédopsychiatrie

  2010cites this paper
• Effects of insomnia and sleep medication on health-related quality of life.

  2010cites this paper
• British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders

  2010cites this paper
• Development of subtype-selective GABAA receptor compounds for the treatment of anxiety, sleep disorders and epilepsy

  2010cites this paper
• circadian rhythm disorders British Association for Psychopharmacology consensus statement on evidence-based treatment of

  2010cites this paper
• Insomnia: A Review of the Use of eszopiclone

  2009cites this paper
• Potentiating effect of eszopiclone on GABA(A) receptor-mediated responses in pedunculopontine neurons.

  2009cites this paper
• Insomnia treatment options for women.

  2009cites this paper
• Minimizing the effect of TBI-related physical sequelae on vocational return.

  2009cites this paper
• Eszopiclone and fluoxetine enhance the survival of newborn neurons in the adult rat hippocampus.

  2009cites this paper
• GABA RECEPTORS ARE INVOLVED IN SLEEP-WAKE PROCESSES, WITH AGENTS ACTING ON GABAA, GABAB, AND EVEN GABAC RECEPTORS EXHIBITING

  2009cites this paper
• Anxiolytics, Sedatives, and Hypnotics

  2009cites this paper
• The Sedating Antidepressant Trazodone Impairs Sleep-Dependent Cortical Plasticity

  2009cites this paper
• Insomnia and its management

  2009cites this paper
• Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

  2008cites this paper
• Insomnia: Therapeutic Options for Women

  2008cites this paper
• Hur inverkar sömnmedel i form av bensodiazepiner och bensodiazepinbesläktade medel på dagtrötthet och frakturrisk hos äldre

  2008cites this paper
• Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

  2008cites this paper
• Pediatric sleep pharmacology.

  2008cites this paper
• Next‐day cognition, psychomotor function, and driving‐related skills following nighttime administration of eszopiclone

  2008cites this paper
• Sleep and geriatric psychopharmacology

  2008cites this paper
• Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial.

  2008cites this paper
• Z-drugs: comparative tolerability

  2008cites this paper
• Pharmacotherapy for insomnia.

  2008cites this paper
• Chapter 6 Sedatives and hypnotics

  2008cites this paper
• Drug Class Review Newer Drugs for Insomnia

  2008cites this paper
• [Recent and potential drugs for treatment of insomnia].

  2007cites this paper